A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy. - A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy.

Kinki University Faculty of Medicine, Nara Hospital0 个研究点目标入组 41 人开始时间: 2011年11月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. No prior treatment with Docetaxel and Bevacizumab 2.History of hemoptysis with 2.5mL per time or more. 3.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 4.massive pleural or pericardial effusion. 5. CNS metastasis 6. Patients with a concomitant or prior invasive malignancy who have had any evidence of the disease within the last 5 years 7. Patients with severe complications Unstable angina. cardiovascular disease, severe heart disease, heart failure within 3month. Uncontrollable diabetes mellitus and hypertension Active infection 8. In pregnancy, during breast feeding, or possibility of pregnancy. 9.The past history of severe allergic reactions 10. psychiatric patients 11. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

发起方

Kinki University Faculty of Medicine, Nara Hospital